Author: Editor

Neha Vapiwala, MD, FACR, FASTRO, Professor and Vice Chair of Education, Radiation Oncology, Associate Dean of Admissions, Perelman School of Medicine, University of Pennsylvania speaks about The New England Journal of Medicine – Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades.     Outline According to the 2020 U.S. Census data, the United States’ population is quickly diversifying. We wanted to see if clinical faculty and leadership representation at academic medical schools reflects the changing demographics of the population. Using data from the Association of American Medical Colleges from 1977 to 2019, we discovered significant progress in female…

Neha Vapiwala, MD, FACR, FASTRO, Professor and Vice Chair of Education, Radiation Oncology, Associate Dean of Admissions, Perelman School of Medicine, University of Pennsylvania speaks about The New England Journal of Medicine – Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades.     Outline According to the 2020 U.S. Census data, the United States’ population is quickly diversifying. We wanted to see if clinical faculty and leadership representation at academic medical schools reflects the changing demographics of the population. Using data from the Association of American Medical Colleges from 1977 to 2019, we discovered significant progress in female…

Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 Abstract – CT108 / 5 – Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence.   Observation –   Origins:   Dendritic cells (DCs) are essential in the anti-tumor immune response. Tumor-induced immunosuppression, on the other hand, promotes DC dysfunction and T cell exhaustion, culminating…

Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 Abstract – CT108 / 5 – Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence.   Observation –   Origins:   Dendritic cells (DCs) are essential in the anti-tumor immune response. Tumor-induced immunosuppression, on the other hand, promotes DC dysfunction and T cell exhaustion, culminating…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. In this video, he speaks about Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.   Observation –   Backstory:   Trastuzumab emtansine is the current standard of care for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose illness has progressed after treatment with an anti-HER2 antibody plus a taxane.   Methodologies:   In patients with HER2-positive metastatic breast cancer…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. In this video, he speaks about Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.   Observation –   Backstory:   Trastuzumab emtansine is the current standard of care for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose illness has progressed after treatment with an anti-HER2 antibody plus a taxane.   Methodologies:   In patients with HER2-positive metastatic breast cancer…

Jennifer M. Kalish, MD, Ph.D., Assistant Professor of Pediatrics, Research Scientist, Director, Beckwith-Wiedemann Syndrome Clinic, at Children’s Hospital of Philadelphia. In this video, she speaks about the AACR 2022 abstract – 5220 – The consequences of 11p15 mosaicism in Beckwith-Wiedemann syndrome/spectrum: Epigenotypes associated with cancer development and necessity for universal tumor screening.     Beckwith-Wiedemann Spectrum Condition (BWSp) is the most prevalent (epi)genetic cancer predisposition disorder. BWSp has a variable clinical course and is caused by epigenetic alterations at two locations on chromosome 11p15. These epigenetic alterations take place post-zygotically, resulting in a patchwork distribution across tissues. Clinical molecular testing…

Jennifer M. Kalish, MD, Ph.D., Assistant Professor of Pediatrics, Research Scientist, Director, Beckwith-Wiedemann Syndrome Clinic, at Children’s Hospital of Philadelphia. In this video, she speaks about the AACR 2022 abstract – 5220 – The consequences of 11p15 mosaicism in Beckwith-Wiedemann syndrome/spectrum: Epigenotypes associated with cancer development and necessity for universal tumor screening.     Beckwith-Wiedemann Spectrum Condition (BWSp) is the most prevalent (epi)genetic cancer predisposition disorder. BWSp has a variable clinical course and is caused by epigenetic alterations at two locations on chromosome 11p15. These epigenetic alterations take place post-zygotically, resulting in a patchwork distribution across tissues. Clinical molecular testing…

Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute of the City of Hope. In this video, they speak about the AACR 2022 Abstract – 5208 – Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer.   Outline   In patients with programmed death ligand 1-positive (PD-L1+) metastatic triple negative breast cancer, the use of immune checkpoint inhibitors (ICI) in combination with chemotherapy is now the standard of care (mTNBC). However, the mechanisms of ICI…

Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute of the City of Hope. In this video, they speak about the AACR 2022 Abstract – 5208 – Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer.   Outline   In patients with programmed death ligand 1-positive (PD-L1+) metastatic triple negative breast cancer, the use of immune checkpoint inhibitors (ICI) in combination with chemotherapy is now the standard of care (mTNBC). However, the mechanisms of ICI…

Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 5682 – Accelerated biological age is a driver of cancer susceptibility in genetic high risk breast tissue.   Outline   Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age by displaying markers normally present in myoepithelial cells. We postulate that loss of lineage fidelity is a common feature of epithelia that is predisposed to cancer initiation. We show that histologically normal breast tissue from younger women who are predisposed to breast cancer due…

Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 5682 – Accelerated biological age is a driver of cancer susceptibility in genetic high risk breast tissue.   Outline   Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age by displaying markers normally present in myoepithelial cells. We postulate that loss of lineage fidelity is a common feature of epithelia that is predisposed to cancer initiation. We show that histologically normal breast tissue from younger women who are predisposed to breast cancer due…

Trey Ideker, Ph.D., UCSD Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives at the University of California, San Diego. In this video, he speaks about the AACR 2022 presentation based on the study – Interpretation of cancer mutations using a multiscale map of protein systems.   Intro:   Tumor genome sequencing has revealed that other than a few typically altered genes, the majority of mutations affecting cancer genomes are uncommon. A powerful technique for interpreting these…

Trey Ideker, Ph.D., UCSD Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives at the University of California, San Diego. In this video, he speaks about the AACR 2022 presentation based on the study – Interpretation of cancer mutations using a multiscale map of protein systems.   Intro:   Tumor genome sequencing has revealed that other than a few typically altered genes, the majority of mutations affecting cancer genomes are uncommon. A powerful technique for interpreting these…

Nada Jabado, MD, Ph.D., Professor of Pediatrics and Human Genetics at McGill University and a staff physician in the Division of Hematology and Oncology at the Montreal Children’s Hospital at McGill University. In this video, she speaks about the AACR 2022 Presentation – Deciphering oncohistone pathogenicity and exquisite vulnerabilities.

Nada Jabado, MD, Ph.D., Professor of Pediatrics and Human Genetics at McGill University and a staff physician in the Division of Hematology and Oncology at the Montreal Children’s Hospital at McGill University. In this video, she speaks about the AACR 2022 Presentation – Deciphering oncohistone pathogenicity and exquisite vulnerabilities.

Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) and cares for patients with a clinical focus on breast cancer from Yale School of Medicine. In this video, she speaks about the abstract Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.   Abstract Goal: Age is one of the most significant risk factors for the development of breast cancer; nevertheless, the underlying etiology between age and breast cancer remains unknown. We previously discovered correlations between epigenetic aging signatures in breast/tumor tissue and breast cancer risk/prevalence. However, these DNA…

Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) and cares for patients with a clinical focus on breast cancer from Yale School of Medicine. In this video, she speaks about the abstract Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.   Abstract Goal: Age is one of the most significant risk factors for the development of breast cancer; nevertheless, the underlying etiology between age and breast cancer remains unknown. We previously discovered correlations between epigenetic aging signatures in breast/tumor tissue and breast cancer risk/prevalence. However, these DNA…

Prof. Dr. Enrique Estrada-Lobato, IAEA Nuclear Medicine Physician. In this video, he speaks about the IAEA’s Support of breast cancer screening along the Amazon River. He also introduces the IAEA’s six decades of experience in helping countries use nuclear techniques to prevent, diagnose and treat cancer. Women in Amazon River villages will have better access to breast cancer screening starting this year, owing to two new mammography devices deployed on Brazilian navy ships delivering crucial health services along South America’s longest waterway. The two devices carried onboard the ships Soares de Meirelles and Carlos Chagas, procured by the International Atomic…

Prof. Dr. Enrique Estrada-Lobato, IAEA Nuclear Medicine Physician. In this video, he speaks about the IAEA’s Support of breast cancer screening along the Amazon River. He also introduces the IAEA’s six decades of experience in helping countries use nuclear techniques to prevent, diagnose and treat cancer. Women in Amazon River villages will have better access to breast cancer screening starting this year, owing to two new mammography devices deployed on Brazilian navy ships delivering crucial health services along South America’s longest waterway. The two devices carried onboard the ships Soares de Meirelles and Carlos Chagas, procured by the International Atomic…

Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, he speaks about the Miami Breast 2022 discussion – Primer in Genomics: Applications to the Clinic in 2022.

Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, he speaks about the Miami Breast 2022 discussion – Primer in Genomics: Applications to the Clinic in 2022.

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr. Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial, and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Debiao Li, Ph.D., Director, Biomedical Imaging Research Institute, Professor, Biomedical SciencesProfessor, Imaging, Principal Investigator at Cedars-Sinai, and Stephen Pandol, MD, Director, Basic and Translational Pancreas Research, Program Director, Gastroenterology Fellowship Program at Cedars-Sinai. In this video, they discuss the article AI and machine learning could improve cancer diagnosis through biomarker discovery.    Many industries and fields of study have been changed by artificial intelligence (AI), deep learning (DL), and machine learning (ML). These techniques are now being used to solve the issues of cancer biomarker development, where huge volumes of imaging and molecular data must be analyzed in ways that…

Debiao Li, Ph.D., Director, Biomedical Imaging Research Institute, Professor, Biomedical SciencesProfessor, Imaging, Principal Investigator at Cedars-Sinai, and Stephen Pandol, MD, Director, Basic and Translational Pancreas Research, Program Director, Gastroenterology Fellowship Program at Cedars-Sinai. In this video, they discuss the article AI and machine learning could improve cancer diagnosis through biomarker discovery.    Many industries and fields of study have been changed by artificial intelligence (AI), deep learning (DL), and machine learning (ML). These techniques are now being used to solve the issues of cancer biomarker development, where huge volumes of imaging and molecular data must be analyzed in ways that…

Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona, and global primary investigator of the ATHENA trial. In this video, he speaks about Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial.   This is a Phase 3 randomized, global, double-blind, dual placebo-controlled, 4-arm research investigating rucaparib plus nivolumab as maintenance treatment in patients with newly diagnosed ovarian cancer who have responded to front-line treatment. The…

Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona and global primary investigator of the ATHENA trial. In this video, he speaks about Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial.   This is a Phase 3 randomized, global, double-blind, dual placebo-controlled, 4-arm research investigating rucaparib plus nivolumab as maintenance treatment in patients with newly diagnosed ovarian cancer who have responded to front-line treatment. The…

Eric Tkaczyk, MD, Ph.D., FAAD, Director Vanderbilt Dermatology Translational Research Clinic, Staff Physician Department of Veterans Affairs, Nashville Dermatology and Research Services, Assistant Professor Department of Dermatology, Assistant Professor Biomedical Engineering at Vanderbilt University Medical Center and Inga Saknite, Ph.D., Adjoint Assistant Professor of Dermatology, Department of Dermatology, Vanderbilt University Medical Center Senior Researcher, Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia. In this video, they speak about a Study Finds 10-Second Videos Predict Blood Cancer Relapse.   A new study from Vanderbilt University Medical Center found that 10-second recordings of white blood cell mobility in the…

Eric Tkaczyk, MD, Ph.D., FAAD, Director Vanderbilt Dermatology Translational Research Clinic, Staff Physician Department of Veterans Affairs, Nashville Dermatology and Research Services, Assistant Professor Department of Dermatology, Assistant Professor Biomedical Engineering at Vanderbilt University Medical Center and Inga Saknite, Ph.D., Adjoint Assistant Professor of Dermatology, Department of Dermatology, Vanderbilt University Medical Center Senior Researcher, Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia. In this video, they speak about Noninvasive Videomicroscopy Predicts Blood Cancer Relapse. A new study from Vanderbilt University Medical Center found that 10-second recordings of white blood cell mobility in the skin ‘s microvasculature considerably…

Nicholas John Maragakis, MD, Director, ALS Center for Cell Therapy and Regeneration Research, Professor of Neurology at Johns Hopkins Medicine. In this video, he speaks about Johns Hopkins Researchers Identify a Potential Window for Treating ALS, as well as, some cancers. Amyotrophic lateral sclerosis (ALS) is a neurological condition that affects up to 30,000 people in the United States each year, with 5,000 new cases reported. It gradually weakens muscles, impairing physical function and eventually leading to death. The condition has no single cause and no recognized remedy. However, Johns Hopkins Medicine researchers have discovered a potential window of opportunity…

Nicholas John Maragakis, MD, Director, ALS Center for Cell Therapy and Regeneration Research, Professor of Neurology at Johns Hopkins Medicine. In this video, he speaks about Johns Hopkins Researchers Identify a Potential Window for Treating ALS, as well as, some cancers. Amyotrophic lateral sclerosis (ALS) is a neurological condition that affects up to 30,000 people in the United States each year, with 5,000 new cases reported. It gradually weakens muscles, impairing physical function and eventually leading to death. The condition has no single cause and no recognized remedy. However, Johns Hopkins Medicine researchers have discovered a potential window of opportunity…

Xianxin Hua, MD, Ph.D., Professor of Cancer Biology at the Abramson Cancer Research Institute, Department of Cancer Biology at the University of Pennsylvania Perelman School of Medicine. In this video, he speaks about the Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.   PHILADELPHIA — Although chimeric antigen receptor (CAR) T cells can be extremely effective in treating leukemias and lymphomas, there are currently no viable immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal malignancies (GICs). Penn Medicine researchers discovered that CAR-T cells directed to a tumor antigen, CDH17, a cell surface…

Xianxin Hua, MD, Ph.D., Professor of Cancer Biology at the Abramson Cancer Research Institute, Department of Cancer Biology at the University of Pennsylvania Perelman School of Medicine. In this video, he speaks about the Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.   PHILADELPHIA — Although chimeric antigen receptor (CAR) T cells can be extremely effective in treating leukemias and lymphomas, there are currently no viable immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal malignancies (GICs). Penn Medicine researchers discovered that CAR-T cells directed to a tumor antigen, CDH17, a cell surface…

Stephanie Halene, MD, Ph.D., Associate Professor of Medicine (Hematology); Chief, Hematology; Director, DeLuca Center for Innovation in Hematology Research, Yale Cancer Center; Assistant Medical Director CRSL, Yale Cancer Center at Yale University;  Toma Tebaldi, Ph.D., Adjunct Assistant Professor, and Giulia Biancon, Ph.D., Postdoctoral Associate at Yale School of Medicine. In this video, they speak about Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies.   Stephanie Halene, MD, Ph.D., cares for patients with hematologic malignancies and works to bridge the gap between the clinic and the basic science laboratories.   Toma Tebaldi, Ph.D., my research aims at understanding the…

Stephanie Halene, MD, Ph.D., Associate Professor of Medicine (Hematology); Chief, Hematology; Director, DeLuca Center for Innovation in Hematology Research, Yale Cancer Center; Assistant Medical Director CRSL, Yale Cancer Center at Yale University;  Toma Tebaldi, Ph.D., Adjunct Assistant Professor, and Giulia Biancon, Ph.D., Postdoctoral Associate at Yale School of Medicine. In this video, they speak about Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies.   Stephanie Halene, MD, Ph.D., cares for patients with hematologic malignancies and works to bridge the gap between the clinic and the basic science laboratories. Toma Tebaldi, Ph.D., my research aims at understanding the RNA…

Debra Dyer, MD, FACR, Professor, a radiologist at National Jewish Health. Dr. Dyer serves as Chair of the Department of Radiology. In this video, she speaks about New Medicare Lung Cancer Screening Guidelines a Huge Step Forward – More Lives to be Saved. As screening becomes more prevalent, providers should pursue quality assurance. New Centers for Medicare and Medicaid Services (CMS) proposals to reduce the initial age and smoking history requirements for lung cancer screening (LCS) could make these exams the most effective cancer screening tests in history. The American College of Radiology® (ACR®), the GO2 Foundation for Lung Cancer,…

Debra Dyer, MD, FACR, Professor, a radiologist at National Jewish Health. Dr. Dyer serves as Chair of the Department of Radiology. In this video, she speaks about New Medicare Lung Cancer Screening Guidelines a Huge Step Forward – More Lives to be Saved. As screening becomes more prevalent, providers should pursue quality assurance. New Centers for Medicare and Medicaid Services (CMS) proposals to reduce the initial age and smoking history requirements for lung cancer screening (LCS) could make these exams the most effective cancer screening tests in history. The American College of Radiology® (ACR®), the GO2 Foundation for Lung Cancer,…

Charles E. Geyer, Jr., MD, FACP, Principal Investigator for NSABP B-55 Portion of the OlympiA Trial, Medical Oncologist & Breast Cancer Specialist, Chief Scientific Officer, NSABP Foundation Pittsburg Pennsylvania. In this video, he speaks about Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.   Abstract – Origins: Poly(adenosine diphosphate–ribose) polymerase inhibitors use synthetic lethality to target tumors with deficiencies in homologous recombination repair. To minimize recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are required.   Methodologies: Patients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, BRCA1 or BRCA2…

Charles E. Geyer, Jr., MD, FACP, Principal Investigator for NSABP B-55 Portion of the OlympiA Trial, Medical Oncologist & Breast Cancer Specialist, Chief Scientific Officer, NSABP Foundation Pittsburg Pennsylvania. In this video, he speaks about Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.   Abstract – Origins: Poly(adenosine diphosphate–ribose) polymerase inhibitors use synthetic lethality to target tumors with deficiencies in homologous recombination repair. To minimize recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are required.   Methodologies: Patients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, BRCA1 or BRCA2…

Julie Wu, MD, Ph.D., Medical Oncology Fellow at Stanford University. In this video, she speaks about the IASLC 2022 Abstract – The Impact of Molecular Driver Mutations on Brain Metastasis Risk Depends on Timing of Brain Metastasis Relative to Diagnosis.   Origins:   Patients with ALK- or EGFR-mutated lung cancer have a higher prevalence of brain metastases (BrM). However, it is unclear if this is attributable to patients’ extended survival, a lack of earlier targeted therapeutic brain penetration, or intrinsic driving biology. Patients who present with BrM at the time of distant metastasis, i.e., synchronous BrM, may be less influenced…

Julie Wu, MD, Ph.D., Medical Oncology Fellow at Stanford University. In this video, she speaks about the IASLC 2022 Abstract – The Impact of Molecular Driver Mutations on Brain Metastasis Risk Depends on Timing of Brain Metastasis Relative to Diagnosis.   Origins:   Patients with ALK- or EGFR-mutated lung cancer have a higher prevalence of brain metastases (BrM). However, it is unclear if this is attributable to patients’ extended survival, a lack of earlier targeted therapeutic brain penetration, or intrinsic driving biology. Patients who present with BrM at the time of distant metastasis, i.e., synchronous BrM, may be less influenced…

Aakash Desai, MD, MPH Hematology-Oncology Fellow at Mayo Clinic. In this video, he speaks about the IASLC 2022 Abstract – Real-World Experience of Lurbinectedin Beyond the Second Line in Small Cell Lung Cancer.   Origins:   Patients with small cell lung cancer (SCLC) have few alternatives for treatment after platinum-based regimens and immunotherapy. The US Food and Drug Administration (FDA) has granted fast approval to lurbinectedin, an alkylating agent, for patients with metastatic SCLC who have progressed on or after traditional frontline therapy.   We describe our institutional experience with lurbinectedin in the third-line context or beyond for SCLC in…

Aakash Desai, MD, MPH Hematology-Oncology Fellow at Mayo Clinic. In this video, he speaks about the IASLC 2022 Abstract – Real-World Experience of Lurbinectedin Beyond the Second Line in Small Cell Lung Cancer.   Origins:   Patients with small cell lung cancer (SCLC) have few alternatives for treatment after platinum-based regimens and immunotherapy. The US Food and Drug Administration (FDA) has granted fast approval to lurbinectedin, an alkylating agent, for patients with metastatic SCLC who have progressed on or after traditional frontline therapy.   We describe our institutional experience with lurbinectedin in the third-line context or beyond for SCLC in…

Eric Collisson, MD, Professor of Medicine at UC San Francisco, and Adam Renslo, Ph.D., Professor, Pharmaceutical Chemistry at UC San Francisco. In this video, they speak about Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.   Overview:   KRAS mutations are responsible for one-quarter of cancer deaths, and the majority are untreatable. Several MAPK pathway inhibitors are FDA-approved, however, they are poorly tolerated at the levels required to effectively suppress RAS/RAF/MAPK signaling in tumor cells. Oncogenic KRAS signaling increased ferrous iron (Fe2+) buildup early in and during mutant KRAS-mediated transformation, we discovered. We were able to establish…

Eric Collisson, MD, Professor of Medicine at UC San Francisco, and Adam Renslo, Ph.D., Professor, Pharmaceutical Chemistry at UC San Francisco. In this video, they speak about Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.   Overview:   KRAS mutations are responsible for one-quarter of cancer deaths, and the majority are untreatable. Several MAPK pathway inhibitors are FDA-approved, however, they are poorly tolerated at the levels required to effectively suppress RAS/RAF/MAPK signaling in tumor cells. Oncogenic KRAS signaling increased ferrous iron (Fe2+) buildup early in and during mutant KRAS-mediated transformation, we discovered. We were able to establish…

Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he speaks about Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Overview: Symptomatic multiple myeloma is distinguished by osteolytic lesions (OL). The methods by which malignant plasma cells (PC) cause OL in one place while not causing bone damage in others despite thorough invasion remain unexplained. We present a prospective single-cell RNA sequencing (scRNA-seq) investigation of PC derived from random bone marrow aspirates (BM) and matched imaging-guided OL biopsies. Based on the scRNA-seq analysis, we examined 148,630…

Kevin Kalinsky, MD, MS, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director, Glenn Family Breast Center, Director, Breast Medical Oncology at Winship Cancer Institute of Emory University at Emory University. In this video, he speaks about the Miami Breast Abstract – Risk Stratification in Early-Stage Hormone Receptor−Positive Breast Cancer.

Kevin Kalinsky, MD, MS, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director, Glenn Family Breast Center, Director, Breast Medical Oncology at Winship Cancer Institute of Emory University at Emory University. In this video, he speaks about the Miami Breast Abstract – Risk Stratification in Early-Stage Hormone Receptor−Positive Breast Cancer.

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about an Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.     Outline   Intent:   Entrectinib inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and has previously elicited profound [57.4 percent] and sustained [median duration of response (DoR) 10.4 months] responses in…